Trip.com Group Faces Securities Investigation Following Antitrust Probe

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Trip.com faces securities investigation following Chinese antitrust probe. Stock dropped 17% after disclosure; investors may pursue class action lawsuit for alleged misleading disclosures.

Trip.com Group Faces Securities Investigation Following Antitrust Probe

The Rosen Law Firm has initiated an investigation into potential securities violations by Trip.com Group Limited (NASDAQ: TCOM) in response to allegations involving materially misleading business disclosures. The inquiry follows a January 14, 2026 announcement by Chinese regulatory authorities regarding an antitrust investigation into the online travel platform's business practices.

The disclosure triggered a significant market reaction, with Trip.com's American Depositary Shares declining 17% following the announcement. The magnitude of the price movement underscores investor concern regarding the regulatory scrutiny and its potential implications for the company's operations and financial performance.

Investors who purchased TCOM securities during the relevant period may have grounds for legal recourse. The Rosen Law Firm is identifying shareholders who may qualify as members of a potential class action lawsuit seeking damages related to alleged misrepresentations or omissions of material information.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 14

Related Coverage

GlobeNewswire Inc.

Plug Power Faces Class Action Over DOE Loan Claims as April Deadline Looms

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

PLUG
GlobeNewswire Inc.

BlackRock TCP Capital Hit by Class Action Over $19B NAV Collapse

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

TCPC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
GlobeNewswire Inc.

Class Action Lawsuit Filed Against China Liberal Education Over Alleged $300M Pump-and-Dump Scheme

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

CLEUF
GlobeNewswire Inc.

METC Faces Class Action Over Brook Mine Claims; Lead Plaintiff Deadline Set for March 31

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

METCMETCBMETCI
GlobeNewswire Inc.

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

IRON